NOBIVAC® Intra-Trac®₃

Intra-Trac®₃

A proven intranasal vaccine that provides triple protection against the agents implicated in the cause of tracheobronchitis (“canine cough”).

Product Description

NOBIVAC^® INTRA-TRAC^®₃ provides protection against Tracheobronchitis (“Canine Cough”)

Canine Adenovirus 2, Canine Parainfluenza Virus (modified live viruses), Bordetella Bronchiseptica (avirulent live culture)

Protects against Bordetella, canine parainfluenza virus, and canine adenovirus type
Offers the superior benefits of intranasal administration
Can be used in puppies as young as 3 weeks of age because maternal antibodies do not interfere with localized antibody response
Requires only single-nostril administration—low dose of 0.5 mL
Provides rapid protection beginning as early as 48 hours post-vaccination against B. bronchiseptica¹⁴
Proven 1-year duration of immunity for B. bronchiseptica¹⁵

product Label

Overview

Safety

Administration

Disease Information

Resources

Indications

This product has been shown to be effective for vaccination of healthy dogs 3 weeks of age or older against canine adenovirus type 2, canine parainfluenza virus and Bordetella bronchiseptica.

NOBIVAC^® INTRA-TRAC^®₃ IS A SAFE CHOICE

Can be used in puppies as young as 3 weeks of age because maternal antibodies do not interfere with localized antibody response
Requires only single-nostril administration—low dose of 0.5 mL
Available with Advanced Delivery Technology (ADT) that eliminates the possibility of accidental injection (Nobivac^® Intra-Trac^® ₃ ADT only)

ADMINISTRATION AND DOSAGE

Designed for intranasal use only with the enclosed applicators
0.4 mL-dose administered directly into 1 nostril
Flexible dosing – For one 1 mL dose, rehydrate vaccine with 1 mL sterile diluent or for one 0.5 mL dose, rehydrate vaccine with 0.5 mL sterile diluent
Historically, annual revaccination has been recommended for this product. The need for this booster has not been established. Contact your veterinarian or manufacturer for more information on revaccination frequency.
Available in a variety of presentations:
25 x 1, 2 x 5, and 150 x 1 dose

ALSO AVAILABLE IN OTHER FORMULATIONS

NOBIVAC® Intra-Trac®₃ ADT

DISEASE INFORMATION

Canine Infectious Respiratory Disease Complex (CIRDC)

Efficacy & Comparisons

NOBIVAC® INTRA-TRAC®₃ EFFICACY

PROMOTES A STRONGER IGA RESPONSE THAN SUBCUTANEOUS VACCINATION^16,17

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque tristique tincidunt turpis. In et tortor quis lorem ultrices bibendum at vel risus.

IgA on mucosal surfaces appears to be more important than systemic responses when it comes to protecting against respiratory pathogens 18,19
- Prevents microbes from adhering to mucosal surfaces of the nose and throat
- Helps clear microbes trapped in mucus at the point of entry
Eliminated Bordetella shedding in controlled challenge 9 weeks after vaccination¹⁶
Significantly reduced cough scores and days of coughing¹⁶

INTRANASAL VS. ORAL AND INJECTABLE

NOBIVAC^® INTRA-TRAC^®₃ INTRANASAL OFFERS ADVANTAGES OVER ORAL AND INJECTABLE VACCINES

*Dant JC, Waszgis B, LaFleur RL, Xu Z, Tarpey I. Duration of Immunity for an Oral Bordetella Bronchiseptica Vaccine. ISCAID Proceedings, Portland, OR, 2018.

Professional Resources and Educational Materials

Keep your clinic and staff informed and aware of diseases and outbreaks.

View More Nobivac^® Resources

Pair Up for Protection

When it comes to dogs in social environments, respiratory protection is essential. Use this conversation starter to discuss full respiratory protection with your clients.

Download

Digital Assets